Ali Ashraf, Kumar Sachin, Kakaria Vinod Kumar, Mohan Anant, Luthra Kalpana, Upadhyay Ashish Dutt, Guleria Randeep
a Department of Pulmonary Medicine and Sleep Disorders , All India Institute of Medical Science , New Delhi , India.
b Department of Medical Oncology, All India Institute of Medical Science , New Delhi , India.
Cancer Invest. 2017 Jul 3;35(6):423-430. doi: 10.1080/07357907.2017.1309547. Epub 2017 May 19.
Promoter DNA hypermethylation of APC, DAPK, and GSTP1 genes was evaluated in biopsy and matched serum of 160 lung cancer patients and 70 controls. In biopsy, 83.1, 83.1, and 78.1% of lung cancer patients and 72.9, 70, and 70% of controls, while in serum, 52.5, 30.6, and 65.6% of lung cancer patients and 14.3, 18.6, and 30% of controls were positive for APC, DAPK, and GSTP1 hypermethylation respectively. We couldn't find any significant role of DNA hypermethylation in lung cancer. However, long follow-up of methylation positive controls will be required to confirm its role for the prediction of lung cancer.
在160例肺癌患者和70例对照者的活检组织及配对血清中，评估了APC、DAPK和GSTP1基因启动子DNA的高甲基化情况。在活检组织中，肺癌患者的APC、DAPK和GSTP1基因高甲基化阳性率分别为83.1%、83.1%和78.1%，对照者分别为72.9%、70%和70%；而在血清中，肺癌患者的APC、DAPK和GSTP1基因高甲基化阳性率分别为52.5%、30.6%和65.6%，对照者分别为14.3%、18.6%和30%。我们未发现DNA高甲基化在肺癌中具有任何显著作用。然而，需要对甲基化阳性对照者进行长期随访，以证实其在肺癌预测中的作用。
